Bayer saw the highest growth of 3.05% in patent filings and 0.95% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.8% and grants by 0.79%. GlobalData’s DataBook provides a comprehensive analysis of Bayer‘s patent filings and grants. Buy the databook here.
Bayer has been focused on protecting inventions in United States(US) with 515 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 61% filings and 47% grants. The United States(US), World Intellectual Property Organization(WIPO), Japan(JP), and European Patent Office(EPO) patent Office are among the top ten patent offices where Bayer is filings its patents. Among the top granted patent authorities, Bayer has 47% of its grants in United States(US), 12% in Japan(JP) and 8% in China(CN).
Corteva could be the strongest competitor for Bayer
Patents related to agricultural biotechnology and genetically modified organism (GMO) lead Bayer's portfolio
Bayer has the highest number of patents in agricultural biotechnology followed by, genetically modified organism (GMO) and climate change. For agricultural biotechnology, nearly 53% of patents were filed and 32% of patents were granted in Q2 2024.
Gene editing related patents lead Bayer portfolio followed by genetically modified seeds, and biocides
Bayer has highest number of patents in gene editing followed by genetically modified seeds, biocides, pesticides, and seeds and traits. For gene editing, nearly 27% of patents were filed and 12% of patents were granted in Q2 2024.
For comprehensive analysis of Bayer's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.